Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE)

Expert Review of Clinical Immunology

Volumn 11, Issue 3, 2015, Pages 319-327

  Sabharwal, Geetika ^a   Craig, Timothy ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

C1 inhibitor; C1 esterase inhibitor; hereditary angioedema; recombinant; recombinant C1 inhibitor; treatment

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4B; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; GESTAGEN; ICATIBANT; TRANEXAMIC ACID; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE DISEASE; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY; APPENDICITIS; BACKACHE; BURN; COLITIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DYSPEPSIA; ENZYME INHIBITION; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HALF LIFE TIME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INFECTION; LARYNX EDEMA; LIPOMA; LONG TERM CARE; MENSTRUATION DISORDER; MYALGIA; NAUSEA; NOSE OBSTRUCTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURAL HEADACHE; PROPHYLAXIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCROTAL SWELLING; SIDE EFFECT; SINUS CONGESTION; SKIN BURNING SENSATION; SNEEZING; TOOTH ABSCESS; TREATMENT INDICATION; URINARY TRACT INFECTION; VERTIGO; XEROSTOMIA; ADOLESCENT; ANGIOEDEMAS, HEREDITARY; ANIMAL; CLINICAL TRIAL (TOPIC); RABBIT; TRANSGENIC ANIMAL;

ADOLESCENT; ANGIOEDEMAS, HEREDITARY; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CLINICAL TRIALS AS TOPIC; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; RABBITS; RECOMBINANT PROTEINS;

EID: 84923371486     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1012502     Document Type: Review

References (35)

1. Bhardwaj N, Craig TJ. Treatment of hereditary angioedema: a review. Transfusion 2014;54(11):2989-96
2. Ghazi A, Grant JA. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics 2013;7:103-13
3. Talavera A, Larraona JL, Ramos JL, et al. Hereditary angioedema: an infrequent cause of abdominal pain with ascites. Am J Gastroenterol 1995;90(3):471-4
4. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139(3): 379-94
5. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001;161(20): 2417-29
6. Bork K, Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol 2013;45(1):7-16
7. US Hereditary angioedema association. Available from: www.haea.org
8. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67(2):147-57
9. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004;114(3):629-37
10. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6(1):24
11. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010;6(1):22
12. Bouillet L, Gompel A. Hereditary angioedema in women: specific challenges. Immunol Allergy Clin North Am 2013; 33(4):505-11
13. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129(2):308-20
14. Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in non-Allergic angioedema. Clin Exp Allergy 2013;43(4):475-82
15. van Veen HA, Koiter J, Vogelezang CJ, et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol 2012; 162(2-3):319-26
16. Coutinho M, Aulak KS, Davis AE. Functional analysis of the serpin domain of C1 inhibitor. J Immunol 1994;153(8): 3648-54
17. Cicardi M, Zingale L, Zanichelli A, et al. C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005;27(3): 286-98
18. Bock SC, Shriver K, Nielson E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986;25(15): 4292-301
19. Plosker GL. Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. BioDrugs 2012;26(5):315-23
20. van Doorn MB, Burggraaf J, Van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005;116(4):876-83
21. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007;47(6):1028-32
22. Reshef A, Moldovan D, Obtulowicz K, et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 2013;68(1): 118-24
23. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126(4): 821-827.e14
24. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012; 42(6):929-35
25. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013;110(4): 295-9
26. Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014;112(2):163-169.e1
27. Farkas H, Csuka D, Veszeli N, et al. Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Proc 2014;35(3): 255-9
28. Hack CE, Relan A, van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012;67(1):123-30
29. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124(4):801-8
30. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363(6):513-22
31. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998;38(6):540-9
32. Available from: https://clinicaltrials.gov
33. Hack CE, Mannesse M, Baboeram A, et al. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs 2012;26(5): 303-13
34. U.S. Food and Drug Administration. Available from: www.fda.gov/downloads/.BiologicsBloodVaccines/.BloodBloodProducts/ApprovedProducts/.LicensedProductsBLAs/.FractionatedPlasmaProducts/UCM405634. pdf
35. Available from: http://reference.medscape. Com